Back to search results

A Study of TLN-254 for Relapsed or Refractory T-cell Lymphoma

This study is testing a drug called TLN-254 to see how well it works in people with T-cell lymphoma that has come back (relapsed) or hasn't responded to previous treatments (refractory). TLN-254 will be taken by mouth. Researchers will be looking at how many participants have their lymphoma shrink or disappear (objective response, complete response, or partial response) over a period of up to two years. The study is looking for about 50 participants who are at least 18 years old and have specific types of T-cell lymphoma. The current status of the study is unclear.

Study design
This is an interventional study with a planned enrollment of 50 participants. It is evaluating the anti-tumor activity of TLN-254 monotherapy.
What's involved
TLN-254 will be administered orally at a specified dose on specified days, depending on your treatment group.
Compensation
Not stated in the trial record.
Follow-up
Researchers will measure how well the treatment works for up to two years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06733441

A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma

Active, Not Recruiting
PHASE1Ages 18+InterventionalTreatment
Treeline Biosciences, Inc.
~50 participants
Updated 2026-08-18 on ClinicalTrials.gov
What's tested:TLN-254

At a glance

Recruiting sites
0 of 5 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage of Participants With Objective Response
Measured over Up to 2 years
+2 more outcomes measured

Conditions

Lymphoma

Explore related trials

Mature T-Cell and NK-Cell Non-Hodgkin LymphomaPrimary Cutaneous T-Cell Non-Hodgkin Lymphoma

NCT06733441

Where you'd take part

This study runs at 5 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • British Columbia Cancer Agency

    Vancouver, British Columbia, Canadano site contact published

  • Memorial Sloan Kettering Cancer Center

    New York, New Yorkno site contact published

  • Sarah Cannon Research Institute

    Nashville, Tennesseeno site contact published

  • Stanford Cancer Institute

    Stanford, Californiano site contact published

  • Washington University School of Medicine

    St Louis, Missourino site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Nodal T-follicular helper (TFH) cell lymphoma angioimmunoblastic; Follicular helper T-cell lymphoma, angioimmunoblastic type (angioimmunoblastic T-cell lymphoma).
Nodal TFH cell lymphoma, follicular type; Follicular helper T-cell lymphoma, follicular type.
Nodal TFH cell lymphoma, not otherwise specified (NOS); Follicular helper T-cell lymphoma, NOS.
PTCL, NOS.
Anaplastic large-cell lymphoma, Alkaline phosphatase (ALK) positive.
Anaplastic large-cell lymphoma, ALK negative.
Sezary syndrome
Mycosis fungoides 3. Participant must have measurable disease at study entry. 4. Freshly biopsied or archival tissue available.

Exclusion

Pregnant or lactating women.
Unable to swallow tablets.

What this trial measures

  • Percentage of Participants With Objective ResponseUp to 2 years
  • Percentage of Participants With CRUp to 2 years
  • Percentage of Participants With PRUp to 2 years